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SUMMARY
Background
Nosocomial infections are a major public health issue and preventative
strategies using probiotics and micronutrients are being evaluated.
Aim
To investigate the efﬁcacy of a mixture of Lactobacillus GG and micronu-
trients in preventing nosocomial infections in children.
Methods
A randomised, double-blind, placebo-controlled trial was conducted in hos-
pitalised children. Children (6 months to 5 years of age) received Lacto-
bacillus GG (6 9 109 CFU/day) together with vitamins B and C and zinc
or placebo, for 15 days, starting on the ﬁrst day of hospitalisation. The inci-
dence of gastrointestinal and respiratory nosocomial infections after dis-
charge was determined by follow-up telephone call at 7 days. After
3 months, another telephone call estimated the incidence of further infec-
tions during follow-up.
Results
Ninety children completed the follow-up. Of 19/90 children with a nosoco-
mial infection (20%), 4/45 children (9%) were in the treatment group and
15/45 (33%) in the placebo group (P = 0.016). Speciﬁcally, 2/45 (4%) chil-
dren in the treatment group vs. 11/45 (24%) children in the placebo group
(P = 0.007) presented with diarrhoea. The duration of hospitalisation was
signiﬁcantly shorter in the treatment group (3.9 days  1.7 vs. 4.9  1.2;
P = 0.003). At the follow-up, a total of 11/45 (24.4%) children in the treat-
ment group had at least one episode of infection compared to 22/45
(48.9%) in the placebo group (P = 0.016).
Conclusion
A mixture containing Lactobacillus GG and micronutrients may reduce the
incidence of nosocomial infections, supporting the hypothesis that this may
represent a valid strategy to prevent nosocomial infections.
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INTRODUCTION
Nosocomial infection is an infection acquired by a patient
in the course of a hospital admission. The deﬁnition of
nosocomial infections includes infections occurring >48 h
after admission and <48 h after discharge.1 Despite recent
scientiﬁc and technological progress, nosocomial infec-
tions remain a major problem in public health. Nosoco-
mial infections complicate treatment, prolong hospital
stay and increase hospitalisation costs. Infection control
has an important role in paediatric hospitals as the inci-
dence of nosocomial infections in children in developed
countries ranges from 5% to 44%, with gastrointestinal
infections and respiratory infections being predomi-
nant.2–4 Children are susceptible to infections that are pre-
ventable in older patients through vaccination or previous
exposure. Speciﬁc factors, such as the lack of immune pro-
teins, the spread of secretions and the exchange of con-
taminated toys while in hospital, are associated with an
increased risk of nosocomial infection.5
Current measures for the prevention of nosocomial
infections in the paediatric setting are often ineffective.
Probiotics may prevent common infections in high-risk
environments, such as day care units. Studies have shown
that probiotics are effective in a range of clinical condi-
tions, particularly in the treatment and prevention of acute
diarrhoeal disorders such as acute gastroenteritis and
antibiotic associated diarrhoea.6–12 However, these conclu-
sions are controversial and the statistical evidence is
weak.13–16 A randomised clinical trial, conducted by Hoj-
sak et al., demonstrated a signiﬁcant reduction in the risk
of gastrointestinal infections (RR = 0.40), the number of
episodes of diarrhoea and vomiting, and the duration of
symptoms, in hospitalised children treated with Lacto-
bacillus GG, compared with patients receiving placebo.17
Moreover, there was a signiﬁcant reduction in the risk of
respiratory tract infections (RR = 0.38) and their duration
(RR = 0.40). However, another trial reported that hospi-
talised children receiving Biﬁdobacterium lactis and Lacto-
bacillus reuteri have a similar incidence of nosocomial
infections compared to the control group.18, 19
Randomised controlled trials have shown that zinc
supplementation during acute diarrhoea reduces the
duration, severity and incidence of further diarrhoeal
episodes.20–24 Malik et al., found that a 2-week course of
prophylactic zinc supplementation may reduce diarrhoea
induced morbidity in infants aged 6–11 months, during
a 5-month follow-up period.25
We performed a randomised, double-blind, placebo-
controlled trial with the aim of evaluating the role of a
mixture containing Lactobacillus GG, vitamins B and C
and zinc in the prevention of nosocomial gastrointestinal
and respiratory tract infections within a paediatric
hospital setting.
METHODS
Population
Ninety previously healthy children between 6 months
and 5 years of age admitted to an Italian paediatric ward
with any cause, between January 2014 and January 2015,
were eligible for this study. We excluded children with a
history of preterm birth, children with immunodeﬁciency
diseases, chronic severe illnesses, and genetic or meta-
bolic disorders and children who had been administered
probiotic and/or prebiotic products before enrolment
(within 7 days of hospitalisation). A 7-day period of
washout of probiotic and/or prebiotic was chosen
because the study was performed during the peak season
of rotavirus, and other viral acute gastroenteritis. A
longer length of no pre/probiotic consumption period
might reduce the sample size. However, the form for the
collection of data also included a question on any
assumption of pre/probiotics within 1 month before
enrolment.
Speciﬁcally, during the enrolment period of 1 year,
1172 children were admitted to the paediatric hospitals
involved in the study; 493 were excluded for prematurity,
severe chronic illness, immunodeﬁciency, genetic or
metabolic disease; 549 were excluded for age <6 months
or >5 years, or use of probiotics and/or prebiotics, and
40 children refused enrolment.
Study design
The study design was a prospective, randomised, dou-
ble-blind, placebo-controlled trial. The tested product
contained Lactobacillus GG (3 9 109 CFU/dose), vita-
min B (B1 1.10 mg, B2 and B6 1.40 mg, B12
1.25 lg), vitamin C (40 mg) and zinc (5 mg). The pla-
cebo was a mixture of the same colour, weight, smell
and taste as the intervention product, however, it did
not contain Lactobacillus GG, vitamins B or C or zinc.
The Lactobacillus GG product and the placebo were
packaged in identical bottles. The product and the pla-
cebo were kindly supplied by the ‘Dicofarm’. Research
staff and patients were unaware of the nature of the
product administered to participants. Paediatric resi-
dents were also involved in the study during their
clinical rotation.
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Intervention
A total of 90 children (mean age 25 months, 50 male)
were enrolled and randomly assigned to two groups (in-
tervention group = 45; placebo group = 45). All enrolled
children completed the follow-up. Patients were ran-
domly assigned to the treatment or control group using
a 1:1 allocation ratio. Randomisation was based on com-
puter-assisted permuted-block scheme, with ﬁxed blocks
size of six by a statistician.
They received either the product or the placebo twice
daily for 15 days starting from the day of hospital
admission. Patients were not allowed to receive any other
product containing probiotics or prebiotics for the dura-
tion of the study. For each enrolled child, the onset of
symptoms suggestive of respiratory or gastrointestinal
nosocomial infection was recorded during the hospital
stay. In addition, two follow-up calls were performed
7 days and 3 months after discharge. By means of the
phone call at the 7th day after discharge, we evaluated
the incidence of nosocomial infections considered as the
episodes of diarrhoea, vomiting and respiratory symp-
toms initiated within 2 days starting from the hospital
discharge. The phone call at the 3rd month was used to
assess the incidence of gastrointestinal and respiratory
infections during the follow-up period that included all
the episodes initiated after the ﬁrst 2 days post
discharge.
Primary and secondary outcomes
The primary outcomes were the incidence of gastroin-
testinal and respiratory nosocomial infection, and the
incidence of gastrointestinal and respiratory tract infec-
tions occurring during the 3-month follow-up period.
Patients with at least one episode of infection were con-
sidered as incident cases. The secondary endpoints were
the duration of hospitalisation for nosocomial infections
and the duration of symptoms for each episode of infec-
tion both nosocomial and during the follow-up period.
A nosocomial infection was deﬁned as the appearance of
symptoms of gastrointestinal or respiratory infection in
the period of time between 48 h after hospital admission
and 48 h after hospital discharge.1 The symptoms to
deﬁne a gastrointestinal nosocomial infections were diar-
rhoea and/or vomiting associated or not to fever and
abdominal pain. The symptoms to deﬁne a respiratory
infection were: cough, runny nose, increased breathing
rate etc. associated or not to fever.
All enrolled children with respiratory infection were
routinely investigated for respiratory syncytial
virus using a commercially available in vitro
immunochromatographic assays for the qualitative detec-
tion of respiratory syncytial virus fusion protein antigen
on nasal swab. Faecal samples of all children with gas-
trointestinal symptoms were routinely investigated for
Rotavirus by searching the facal antigen using an
enzyme-linked immunosorbent assay-based test. Inﬂu-
enza virus (detected by a commercially available
immunochromatographic assays for inﬂuenza A and B
virus nucleoproteins), Adenovirus (searched by an
enzyme-linked immunosorbent assay-based test) and Sal-
monella (searched by standard faecal culture) were tested
in selected patients basing on clinical and epidemiologi-
cal criteria.
Parents of participants were speciﬁcally instructed
during the informed consent process to record any
symptom of respiratory or gastrointestinal infection
occurring after discharge from hospital.
Paediatric residents entered the data regarding product
consumption, infections and adverse effects in the
patient’s study diary.
The study protocol was approved by the Ethics Com-
mittee ‘Carlo Romano’ of the University of Naples Fed-
erico II. Written informed consent was obtained from
the parent of each child included in the study. This trial
was formally registered as a clinical trial at Clinical
Trial.gov (NCT02558192).
Statistical analysis
Statistical analysis was performed using R statistical
computing software (R Foundation for Statistical Com-
puting, Vienna, Austria). Descriptive statistics,
frequency and percentages or mean  s.d., were used
to describe the baseline characteristics of patients in
the two groups.
The association between the treatment group and the
primary outcomes was assessed using Chi-square test
and was further quantiﬁed by estimating the odds ratio
(OR) with the corresponding 95% conﬁdence intervals
(95% CI). To evaluate whether breastfeeding and antibi-
otics usage modulated the relative efﬁcacy of probiotics
on the primary end points, the Breslow–Day chi-square
statistics was used as recommended.26 A t-test was used
to evaluate the differences between the treatment and
placebo group in case of numerical variables. Kaplan–
Meier (KM) curves were used to estimate the probability
of remaining free of infection and the univariate hazard
ratio (HR) was computed using the Cox Proportional
Hazard model. Statistical analysis was planned on the
intention-to-treat basis. All tests were two-sided, and a
P < 0.05 was deemed signiﬁcant.
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The sample size of the study was calculated on the
assumption of a 35% incidence of nosocomial infection
and by considering as clinically relevant an absolute
reduction in the risk of infection equal to 25%. A sample
size of 43 subjects in each group was deemed sufﬁcient
to detect such a reduction, if truly present, with a power
of 80% and a two-sided signiﬁcance level of 5%. Allow-
ing for a dropout rate of 5%, 45 patients were enrolled
in each group.
RESULTS
Characteristics of population
There was no clinically signiﬁcant difference between
the groups, in terms of age, gender, weight, height,
body mass index (BMI) and the educational level of
parents (Table 1). The most common reason for hospi-
talisation in all patients was an acute infection. By a
check on the RCT form, none of the enrolled children
assumed probiotics or prebiotics within 1 month before
the enrolment.
Incidence of nosocomial infection
Ninety-two per cent of enrolled patients were allocated
to hospital wards with an average of four patients per
room (1 s.d.). Each room contained a sink and diaper
disposal units.
A total of 19/90 children presented with an episode of
nosocomial infection (20%). The number of children with
nosocomial infection was signiﬁcantly lower in the inter-
vention group compared to the placebo group (4/45 vs.
15/45, OR = 0.2; 95% CI: 0.06–0.65; P = 0.008; Table 2).
The relationship between treatment and incidence of
nosocomial infection was homogenous by breastfeeding
(Breslow–Day chi square = 1.26, P = 0.262) and antibiotic
usage (Breslow–Day chi square = 3.05, P = 0.081).
This was particularly evident for gastrointestinal infec-
tions. Only 2/45 (4.4%) children in the treatment group
vs. 11/45 (24.4%) children in the placebo group devel-
oped a gastrointestinal nosocomial infection (OR = 0.14;
95% CI: 0.03–0.69; P = 0.016). No difference in the inci-
dence of respiratory tract nosocomial infections was
observed between the two groups (2/45 vs. 4/45;
P = 0.407; Table 2).
There were signiﬁcant differences between the two
groups in the secondary endpoints related to nosocomial
infections. The mean duration of hospitalisation was sig-
niﬁcantly lower in patients in the intervention group
compared with the placebo group (3.9 days  1.6 vs.
4.9  1.2 days, respectively; P = 0.001; Table 3). The
duration of hospitalisation was signiﬁcantly shorter for
gastrointestinal nosocomial infections in the treatment
group compared to the placebo group (1.5 days vs.
4.4 days; P = 0.0017); however, no difference was
observed for respiratory infections.
Effects of the treatment in the follow-up period
A total of 33/90 (37%) children had at least one episode of
infection during the 3-month follow-up period; of these,
11/45 (24.4%) children were in the intervention group and
22/45 (48.9%) children were in the placebo group (OR:
0.34; 95% CI: 0.14–0.84; P = 0.016). Neither breastfeeding
Table 1 | Baseline characteristics of enrolled patients
Variable
Intervention*
(n = 45)
Placebo
(n = 45)
Age, months, mean  s.d. 33.8  17.4 34.7  17.2
Female gender, n (%) 21 (47) 19 (42)
Exclusive brestfeeding, n (%) 18 (40.9) 15 (35.7)
Duration of brestfeeding
in months, mean  s.d.
10.1  6.1 11.1  5
Weight in kg, mean  s.d. 12.2  3.8 12.4  4.2
Height in cm, mean  s.d. 86.4  20.1 86.8  16.9
BMI as kg/m2, mean  s.d. 18.09  5.43 16.42  1.79
Reason for hospitalisation, n (%)
Acute gastroenteritis 9 (20) 8 (17.8)
Respiratory tract infection 17 (37.8) 12 (26.7)
Fever 12 (26.7) 16 (35.6)
Other 7 (15.5) 9 (20)
s.d., standard deviation; BMI, body mass index.
* LGG+micronutrients
Table 2 | Effect of treatment on the occurrence of nosocomial infections
Outcome Intervention* (n = 45) Placebo (n = 45) OR (95% CI) P
Overall nosocomial infections, n (%)† 4 (8.8) 15 (33.3) 0.2 (0.06–0.65) 0.008
Nosocomial gastrointestinal infections, n (%)† 2 (4.4) 11 (24.4) 0.14 (0.03–0.69) 0.016
Nosocomial upper respiratory tract infections, n (%)† 2 (4.4) 4 (8.8) 0.48 (0.08–2.75) 0.407
* LGG+micronutrients.
† Number and percentages of children with at least one episode of infection.
Aliment Pharmacol Ther 2016; 44: 568–575 571
ª 2016 John Wiley & Sons Ltd
Randomised clinical trial: probiotic & micronutrient reduces nosocomial infections
(Breslow–Day chi square = 0.03, P = 0.852) nor antibiotic
usage (Breslow–Day chi square = 0.67, P = 0.413) acted
as effect modiﬁer of this association.
The main effect was observed for gastrointestinal
infections with 5/45 children in the intervention group
showing at least one episode of gastrointestinal infection
compared to 14/45 children in the placebo group (OR:
0.29; 95% CI: 0.08–0.84; P = 0.020). No difference in the
incidence of respiratory tract infections was observed (6/
45 children in the intervention group vs. 8/45 children
in the placebo group; P = 0.56).
A total of 40 infectious episodes were recorded during
the 3-month follow-up period: 13/40 (32%) infectious
episodes occurred in the intervention group and 27/40
(60%) episodes in the placebo group. The mean inci-
dence of infections during the follow-up period was
0.28  0.08 episodes/child/3 months in the treatment
group compared to 0.6  0.1 episodes/child/3 months in
the placebo group (P = 0.02). Again, the effect was sig-
niﬁcant for gastrointestinal infections in the intervention
group compared with placebo (0.11  0.04 vs.
0.33  0.07, respectively; P = 0.016), whereas no differ-
ence was found in the incidence of respiratory tract
infections between the two groups (0.17  0.06 vs.
0.28  0.09; P = 0.43; Figure 1).
Furthermore, the mean duration of symptoms over the
3-month follow-up period was signiﬁcantly reduced in the
intervention group compared to the placebo group
(3.9  1.6 vs. 4.9  1.2 days respectively, P = 0.03; Fig-
ure 2).
Cox regression analysis showed a 56% reduction in
the risk of infections in patients in the intervention
group compared to the placebo group (HR = 0.44; 95%
CI: 0.22–0.89; P = 0.023). The corresponding KM curves
representing the probability of remaining infection-free
are shown in Figure 3.
DISCUSSION
Nosocomial infections are the most frequent and severe
complication of hospitalisation. Furthermore, they have
signiﬁcant repercussions on healthcare costs and are indi-
cators of the quality of service provided to in-patients.
Despite the signiﬁcant impact of nosocomial infections,
surveillance systems and strategies to minimise their con-
sequences often remain ineffective. Studies have shown
that prevention of infections results in lower healthcare
costs and improved services and that further preventive
measures are necessary to minimise the risk of hospital-
acquired infections. One of the potential strategies for the
prevention of nosocomial infections is the use of probi-
otics. While there is strong evidence of their efﬁcacy in dif-
ferent clinical conditions, such as acute gastroenteritis and
antibiotic associated diarrhoea,10, 11 the role of probiotics
in the prevention of nosocomial infections is controversial
and the results are not uniform.
Our aim was to evaluate the effects of a mixture con-
taining Lactobacillus GG, zinc and vitamins in the pre-
vention of nosocomial infection in children. The
Table 3 | Effect of treatment on the occurrence of vomiting/diarrhoea episodes and on the duration of hospital stay
Outcome Intervention* (n = 45) Placebo (n = 45) OR (95% CI) P
Nosocomial vomiting episodes, n (%)† 10 (22.2) 9 (20) 1.14 (0.42–3.15) 0.796
Nosocomial diarrhoeal episodes, n (%)† 11 (24.4) 12 (26.7) 0.89 (0.35–2.3) 0.809
Duration of hospital stay, mean  s.d. 3.9  1.6 4.9  1.2 – 0.003
s.d., standard deviation.
* LGG+micronutrients
† Number and percentages of children with at least one episode of vomiting/diarrhoea.
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Figure 1 | During a 3-month follow-up period the
incidence of infections in children supplemented with
LGG and micronutrients was signiﬁcantly reduced
compared to placebo group (P = 0.02). The main effect
was observed in the incidence of gastrointestinal
infections (P = 0.016) whereas no difference was
observed in the incidence of respiratory infections.
* P < 0.05.
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relatively high incidence of nosocomial infection
observed is explained by the target population, and tim-
ing of the study which was conducted during the peak
season of rotavirus, inﬂuenza and respiratory syncytial
virus infections, the most frequent nosocomial infections
in infants and young children. Our study shows that
treatment with probiotics and micronutrients, started
within 24 h of hospital admission and continued for
2 weeks, reduces the incidence of nosocomial infections.
This ﬁnding was statistically signiﬁcant only in the con-
text of gastrointestinal infections. The lack of a
statistically signiﬁcant difference in the incidence of res-
piratory tract infections may be explained by the small
number of enrolled children. We calculate the sample
size basing on the primary outcome that was the reduc-
tion in nosocomial infections regardless the site of the
infection. To establish the effect on respiratory infection
the number needed to enrol should be higher and fur-
ther larger scale studies are needed to further explore
this option.
Our study supports the efﬁcacy of Lactobacillus GG,
as demonstrated in previous studies.17 Hojsak et al., in a
randomised, controlled, double-blind clinical trial,
demonstrated that the administration of Lactobacillus
GG results in a signiﬁcant reduction in the risk of gas-
trointestinal infections as well as episodes of gastroen-
teritis lasting more than 2 days.18 Similar results were
observed following the administration of Lactobacillus
GG to children admitted to a day care centre, another
setting associated with an increased risk of common res-
piratory and intestinal infections.27
In a meta-analysis, Szajeska et al., showed that the
administration of Lactobacillus GG signiﬁcantly reduced
the incidence of nosocomial diarrhoea (2 RCTs, n = 823,
RR = 0.37, 95% CI: 0.23–0.59) and of symptomatic rota-
virus gastroenteritis (3 RCTs, n = 1043, RR = 0.49, 95%
CI: 0.28–0.86) compared to placebo.13 It is not clear
whether the efﬁcacy of the product in our study was
entirely due to the probiotic or to one or more of the
added micronutrients. There is evidence that Lactobacil-
lus GG prevents nosocomial infections.17 There is also
evidence supporting the use of zinc in children with
impaired nutritional status.28 However, a recent research
showed that daily zinc but not multivitamin supplemen-
tation reduces the burden of diarrhoea and respiratory
tract infections in Tanzanian infants.29 A recent study
showed that the administration of a mixture of four pro-
biotic strains together with vitamin C was able to reduce
the burden of upper respiratory infection in children
attending pre-school.30
Therefore, our ﬁndings support the strategy of pre-
scribing probiotic and micronutrients in conditions of
increased exposure to common childhood infections,
such as hospital admission, however, the optimal choice
and dose of bacteria and micronutrients, as well as the
optimal duration of the intervention, remain unclear.
Finally, an interesting aspect of our study is that we
enrolled children admitted to hospital, regardless of their
speciﬁc illness, so our trial was conducted in a real set-
ting of paediatric general hospital and the obtained
results may be considered representative of a ﬁeld trial.
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Figure 2 | The mean duration of symptoms of infection
during the follow-up period was signiﬁcantly shorter in
children who received LGG and micronutrients
compared to children received placebo (P = 0.03).
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Our data show that the duration of hospitalisation is
reduced by 1 day in the treatment group compared to
the placebo group. This result is important because it
has not been shown in previous studies, although it has
been reported that the administration of Lactobacillus
GG in children hospitalised for diarrhoea results in
earlier discharge from hospital.
However, unlike previous studies, we did not ﬁnd any
statistically signiﬁcant difference in the incidence of res-
piratory tract infections. This could be explained by the
fact that our study was powered to detect a reduction in
the overall infection rate, and not speciﬁcally of gastroin-
testinal or respiratory tract infections.
Interestingly, we found that children in the treatment
group had a lower incidence of gastrointestinal infec-
tions compared to children in the placebo group over
the 3-month follow-up period. As shown in Figure 3
children treated with the mixture of Lactobacillus GG
and micronutrients showed an increased probability of
staying without infection after about 21 days. These data
are relative to the infectious episodes during the
3 months of follow-up and not to the nosocomial infec-
tions.
Furthermore, symptoms duration and severity were
reduced. This evidence of a prolonged effect in the pre-
vention of infection, beyond the treatment period has
been previously reported in children with cystic ﬁbrosis31
and is likely to be related to a long-term effect of Lacto-
bacillus GG on immunity.
Limitations of the study
We are aware of a number of limitations in our study.
Difﬁculties with patient enrolment have limited the sam-
ple size. We observed a reluctance to participate in the
study, which is likely to be associated with a number of
variables, such as a low educational level of the legal
guardians and misinterpretation, including several warn-
ings, in the informed consent form. The population
enrolled largely comprised low school and junior high
school graduates.
Another limitation is the lack of established protocols
on dose and duration of probiotic treatment for our
speciﬁc clinical context. We therefore adopted the probi-
otic dose recommended by the European Guidelines32
for the treatment of acute gastroenteritis and set our
own parameters for the timeframe of probiotic
treatment.
CONCLUSIONS
The use of a mixture containing Lactobacillus GG and
micronutrients is effective in reducing the incidence of
nosocomial infections, speciﬁcally gastrointestinal infec-
tions. Treatment reduced the length of hospitalisation in
a population of children in whom the main cause of
admission was an infection itself. Furthermore, the effect
on prevention of infectious diseases was observed beyond
the duration of hospitalisation.
These results support the hypothesis that the adminis-
tration of Lactobacillus GG and micronutrients provide a
valid strategy in the prevention of hospital-acquired
infections.
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